Artiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Misses Expectations By $0.24 EPS

Artiva Biotherapeutics (NASDAQ:ARTV) announced its quarterly earnings data on Tuesday. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24), Zacks reports.

Artiva Biotherapeutics Trading Down 4.2 %

Shares of ARTV traded down $0.49 during midday trading on Thursday, reaching $11.21. 7,441 shares of the stock were exchanged, compared to its average volume of 138,615. The firm has a 50 day moving average price of $12.60. Artiva Biotherapeutics has a 52 week low of $9.68 and a 52 week high of $17.31.

Wall Street Analysts Forecast Growth

ARTV has been the topic of several research reports. Cantor Fitzgerald initiated coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a “buy” rating and a $21.00 target price for the company. Finally, TD Cowen assumed coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a “buy” rating on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $21.25.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.